Filing Flows › Neogenomics (NEO) › Q3 2026 › vs Q2 2026
Neogenomics (NEO) Q3 2026 vs Q2 2026 (quarter over quarter)
Neogenomics's revenue rose $7.6M (+4%) from $202M in Q2 2026 to $209M in Q3 2026. The biggest changes: Commercial insurance +$8.4M (+23%); Client direct billing −$2.4M (-2%); Medicare and other government +$1.6M (+6%).
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Client direct billing | $136M | $138M | −$2.4M | -2% |
| Commercial insurance | $44.7M | $36.3M | $8.4M | +23% |
| Medicare and other government | $29.0M | $27.4M | $1.6M | +6% |
| Revenue | $209M | $202M | $7.6M | +4% |
| Income tax benefit | $475K | $412K | $63K | +15% |
| Net loss | $7.5M | −$2.2M | $9.8M | — |
| Costs & expenses | $217M | $214M | $3.6M | +2% |
| Operating costs | $217M | $211M | $5.8M | +3% |
| Cost of revenue | $113M | $110M | $2.9M | +3% |
| Research & development | $9.9M | $10.8M | −$906K | -8% |
| Sales & marketing | $27.6M | $27.3M | $326K | +1% |
| General & admin | $67.1M | $63.6M | $3.5M | +5% |
| Operating cash sources | $33.9M | $4.5M | $29.4M | +659% |
| Depreciation & amortization | $16.2M | $16.2M | −$21K | -0.1% |
| Share-based compensation | $8.8M | $8.2M | $621K | +8% |
| Cash used in operations | $8.9M | −$20.0M | $28.8M | — |
| Net loss absorbed | $7.5M | −$2.2M | $9.8M | — |
| Working capital & other | $26.4M | $6.7M | $19.7M | +293% |
Questions
How much did Neogenomics's revenue grow quarter over quarter in Q3 2026?
Neogenomics's revenue rose $7.6M (+4%) from $202M in Q2 2026 to $209M in Q3 2026.
What drove Neogenomics's revenue change in Q3 2026?
Commercial insurance +$8.4M (+23%); Client direct billing −$2.4M (-2%); Medicare and other government +$1.6M (+6%).